Placeholder

Addressing Reimbursement During Development

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Increasingly in the United States and in Europe, payers and stakeholders are making a more rigorous assessment of the value new pharmaceutical products bring to the table; therefore, pharmaceutical companies are under increasing pressure to demonstrate a product’s benefit to justify reimbursement.


Sidebars:
Ensuring Market Access
Global Health Trends

Experts
Susan Capps. Executive Director, Global Pricing and Payer Planning, Amgen, a biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics. For more information, visit amgen.com.
Stephanie Dyson. Senior Director, Government Affairs, Genentech, a biotechnology ­company that discovers, ­develops, manufactures and ­commercializes ­medicines to treat patients with serious or life-threatening medical conditions. For more information, visit gene.com.
Timothy Fitzgerald. CEO, GfK Bridgehead, a market access consultancy serving global ­companies in the ­pharmaceutical, medical device, and ­diagnostics industries. For more ­information, visit bridgehead.com.
Jim Furniss. Director, Market Access, GfK Bridgehead, a market access consultancy serving global ­companies in the pharmaceutical, medical device, and diagnostics industries. For more information, visit bridgehead.com.

FEEDBACK